Intravenous Immunoglobulin (IVIG)
A solution of antibodies collected from human plasma. In Kawasaki disease, it is critical for preventing coronary artery aneurysms.
Dosage by Body Weight
Kawasaki Disease: 2 g/kg as a single IV infusion over 10-12 hours. ITP: 0.4 to 1 g/kg/day for 2-5 days.
- Body Weight
- 10-20 kg
- Dose
- 20 g to 40 g
- Frequency
- Single dose (Kawasaki)
- Tracking Notes
- Monitor for transfusion reactions and fluid overload.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| 10-20 kg | 20 g to 40 g | Single dose (Kawasaki) | Monitor for transfusion reactions and fluid overload. |
Formulation
Purpose
Treatment of Kawasaki Disease, Immune Thrombocytopenic Purpura (ITP), and primary immunodeficiency.
Generic Name
Human Normal ImmunoglobulinBranded Drug Names
Intravenous Immunoglobulin (IVIG) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.
Alternatives
Safety Advice
Alcohol
CAUTIONIntravenous Immunoglobulin (IVIG): Alcohol can increase liver strain, stomach irritation, or immune-related complications. Avoid alcohol unless your specialist allows it.
Pregnancy
CAUTIONIntravenous Immunoglobulin (IVIG): Use in pregnancy only under specialist advice because immune, cancer, or transplant treatment requires careful risk assessment.
Breast Feeding
CAUTIONIntravenous Immunoglobulin (IVIG): Breastfeeding may not be recommended with some immunosuppressive or chemotherapy medicines. Follow specialist advice.
Driving
CAUTIONIntravenous Immunoglobulin (IVIG): May cause dizziness, fatigue, nausea, or weakness. Avoid driving if affected.
Liver
CAUTIONIntravenous Immunoglobulin (IVIG): Can affect liver function and usually requires regular blood tests. Use only with specialist monitoring.
Kidney
CAUTIONIntravenous Immunoglobulin (IVIG): Kidney function may need close monitoring, particularly with calcineurin inhibitors or high-risk regimens.